NDAORALTABLET
Approved
Apr 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MILTOWN (meprobamate) by Bausch Health is clinical pharmacology meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications. First approved in 1955.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Miltown (meprobamate) is an oral anxiolytic tablet approved in 1955 for short-term relief of anxiety symptoms. It is a carbamate derivative that acts on multiple CNS sites including the thalamus and limbic system to reduce anxiety. This product represents one of the earliest synthetic anxiolytics and established the carbamate class for psychiatric use.
LOE Approaching
As LOE approaches, Miltown faces significant portfolio pressure; the brand team is likely focused on defensive positioning and managed decline rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system.
Worked on MILTOWN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.